Citius Oncology advances LYMPHIR launch and global expansion

Citius Pharmaceuticals ( (CTXR) ) has provided an announcement.

On March 31, 2026, Citius Oncology reported early commercial progress for LYMPHIR’s U.S. launch in CTCL, citing strong institutional uptake, repeat orders, and approximately 135 health plans providing coverage representing about 80% of covered lives. The company noted formulary adoption at 83% of target accounts, an absence of reimbursement denials or prior-authorization barriers, and the start of penetration into community infusion centers, supported by ongoing commercial buildout and medical education efforts.

Citius Oncology also highlighted that commercial supply is adequate and that international expansion has begun through distribution agreements in Europe and the Middle East. In parallel, LYMPHIR’s clinical development is broadening via investigator-led studies in diffuse large B-cell lymphoma and solid tumors, underpinning management’s strategy to position the drug as a combination immunotherapy across wider oncology settings and reinforcing its long-term role in the company’s portfolio and competitive standing.

The most recent analyst rating on (CTXR) stock is a Hold with a $0.72 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.

Spark’s Take on CTXR Stock

According to Spark, TipRanks’ AI Analyst, CTXR is a Neutral.

The score is primarily constrained by ongoing large losses and sustained cash burn despite a low-debt balance sheet. Technicals are neutral with a short-term bounce but longer-term weakness. Valuation is penalized by negative earnings and no dividend, while recent positive early-stage LYMPHIR trial updates provide a modest offset.

To see Spark’s full report on CTXR stock, click here.

More about Citius Pharmaceuticals

Citius Oncology, Inc. is an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals that develops and commercializes targeted cancer therapies. The company’s lead product, LYMPHIR (denileukin diftitox-cxdl), was approved by the FDA and launched in the U.S. in December 2025 for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma, addressing an initial market estimated above $400 million that management views as growing and underserved.

Average Trading Volume: 531,924

Technical Sentiment Signal: Strong Sell

Current Market Cap: $15.22M

See more insights into CTXR stock on TipRanks’ Stock Analysis page.